AI-Driven Disease Modeling Takes Focus at JSMO 2026
At JSMO 2026 in Yokohama, BostonGene shared how its disease modeling platform is helping advance precision oncology. By integrating diverse data sources, the approach supports better prediction of treatment outcomes, improved clinical trial design, and more informed therapeutic decisions. The model is increasingly being used by biopharma partners to strengthen research and patient care.
Read more on how AI is transforming oncology and drug development: https://bostongene.com/news-an....d-publications/news/